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Identity 
Other names: ANOP3; MCOPS3; MGC2413 




There is an SOX2OT (SOX2 overlapping transcript) 
that encodes a non-coding RNA. SOX2OT contains at 
least five exons and is transcribed into a mRNA of 
about 3.4 kb from the same strand as SOX2. 
Description 
SOX2 is a single exon gene that encodes a member of 
the SRY-related HMG-box (SOX) family of 
transcription factors. The SOX2 single exon contains 
the 5' untranslated region, CDS region and the 3' 
untranslated region (427 bp, 954 bp, 1122 bp). The 
HMG box is a DNA binding domain that is highly 
conserved throughout eukaryotic species. 
Transcription 
The 2503 bases of human SOX2 mRNA contains an 
open reading frame of 954 bases, resulting in a protein 
of 318 amino acid residues. 
 
A picture showing the relationship between SOX2 and SOX2OT (adapted from http://genome.ucsc.edu). 
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The 3D structure for the ternary complex of the DNA binding domains of the Oct1 and Sox2 transcription factors with a 19mer 
oligonucleotide [5'- D(Tpgptpcptptptpgptpcpaptpgpcptpapaptpg) -3'], left view (http://oca.weizmann.ac.il/oca-bin/ccpeek?id=1O4X). The 




The SOX2 protein binds to DNA. The 3D structure for 
the ternary complex of the DNA binding domains of 
the Oct1 and Sox2 transcription factors with a 19mer 
oligonucleotide was solved (Williams et al., 2004; 
http://oca.weizmann.ac.il). 
Expression 
SOX2 is overexpressed in stem cells and many 
different kinds of cancer cells, including glioma, breast 
cancer, colorectal cancer and etc. 
Localisation 
Nucleus and cytoplasm. 
Function 
SOX2 is involved in the regulation of embryonic 
development and in the determination of cell fate. 
SOX2 is one of the four transcription factors (SOX2, 
KLF4, OCT4 and c-Myc), whose over expression can  
induce pluripotency in both mice and human somatic 
cells (Takahashi and Yamanaka, 2006; Takahashi et al., 
2007). Again, SOX2 is one of the genes in another set 
of four factors (OCT4, SOX2, NANOG and LIN28) 
that were able to reprogram human somatic cells to 
pluripotent stem cells and that exhibit the essential 
characteristics of embryonic stem (ES) cells (Yu et al., 
2007). SOX2 is one of the two factors (SOX2 and 
OCT4) that were sufficient to generate induced 
pluripotent stem cells from human cord blood cells 
(Giorgetti et al., 2010). 
Homology 
So far, twenty SOX genes have been identified in 
humans and mice and they can be divided into 10 
subgroups on the basis of sequence similarity and 
genomic organization (Bowles et al., 2000; Schepers et 
al., 2002). SOX genes bind to the minor groove in 
DNA to control diverse developmental processes 
(Wegner, 1999). Three genes, SOX1, SOX2 and SOX3, 
show the closest homology to SRY and share the 
maximum homology within the HMG domain. These  
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genes also share significant homology outside the 




Mutations in SOX2 cause anophthalmia (no eye), 
microphthalmia (small eye) and associated ocular 
developmental anomalies. Fantes identified two 
nonsense amino-acid changes (S83X and E93X) in the 
HMG box (high-mobility group DNA-binding domain), 
which could lead to ablate DNA binding (Fantes et al., 
2003). They also observed a recurrent de novo 
nonsense mutation (529C->T resulting in the amino-
acid change Q177X) (Fantes et al., 2003). Additional 
mutations were later reported for new cases (Bakrania 
et al., 2007; Pedace et al., 2009; Williamson et al., 
2006). SOX2 mutation also caused hearing loss, and 
brain anomalies (Hagstrom et al., 2005), 
hypogonadotropic hypogonadism (Sato et al., 2007), 




SOX2 expression was found to be highly expressed in 
almost all glioma samples. In agreement with the 
heterogeneity of the cell population present in each 
glioma, typically containing cells at various stages of 
differentiation, SOX2 is expressed in a highly variable 
percentage of cells, in the range of 6%-80% in different 
samples (Annovazzi et al., 2011; Gangemi et al., 2009). 
Disease 
Gliomas are the primary cancers derived from glial 
cells in the brain. It is the most frequent cerebral 
neoplasias. Astrocytomas are the most common type of 
gliomas. They are slow-growing, and can be found 
anywhere in the brain, but most often found in the 
cerebrum. They can be clinically divided into four 
grades, with glioblastoma (World Health Organization 
grade IV) being the most common and aggressive. 
Lung cancer (small cell lung cancer; 
lung squamous cell carcinomas) 
Note 
SOX2 was detected in 50% SCLC cell lines. Hussenet 
et al. identified SOX2 as an oncogene and likely driver 
gene of one of the most frequent amplification sites n 
lung SCC (Hussenet et al., 2010; Sholl et al., 2010a; 
Sholl et al., 2010b). 
Disease 
Lung cancer results from the uncontrolled growth of 
abnormal cells in lungs. It is the leading cause of 
cancer death for both men and women. Close to 90 
percent of lung cancers are smoking related.  
Small cell lung cancer (SCLC) is a highly aggressive 
form of lung cancer that accounts for approximately 
20% of all cases of lung cancer. SCLC is a carcinoma 
of neuroendocrine origin, in contrast to non-SCLC 
(NSCLC), which is of bronchial epithelial origin.  
Squamous cell carcinoma (SCC) of the lung is a 
frequent and aggressive cancer type. It is closely 
correlated with a history of tobacco smoking, more so 
than most other types of lung carcinoma (Hussenet et 
al., 2010). 
Gastric cancer (stomach cancer) 
Note 
SOX2 expression was significantly down-regulated in 
gastric carcinoma tissues compared with normal gastric 
epithelia. SOX2 could induce cell-cycle arrest 
associated with decreased levels of CCND1 and 
phosphorylated Rb, and up-regulated p27Kip1 level 
(Otsubo et al., 2008). 
Disease 
Gastric cancer, commonly referred to as stomach 
cancer, forms in tissues that line the stomach. 
Adenocarcinomas is the most comnon type (90-95%), 
but there are other types of stomach cancer including 
squamous cell carcinoma, lymphoma, and stromal 
tumors. Gastric cancer is the second most frequent 
cause of death from cancer in both sexes in the world. 
Breast cancer 
Note 
SOX2 nuclear protein level was highly associated with 
basal-like phenotype in human breast cancer. 
Knockdown of SOX2 could inhibit tumorgenesis in 
vitro and in vivo (Chen et al., 2008). 
Disease 
Breast cancer forms in the tissues of one or both 
breasts. It primarily affects women, but can also occur 
in children and men. It can be a highly curable disease 
if detected and treated early. 
Colorectal cancer 
Note 
SOX2 expression in colorectal cancer tissues was 
found overexpressed in the cancerous tissues compared 
to normal adjacent tissues. Knockdown of SOX2 in 
colorectal cancer cells decreased their growth rates in 
vitro cell line and in vivo in xenograft models (Fang et 
al., 2010). 
Disease 
Colorectal cancer is the second most common 
malignancy in cancer patients and cause of cancer-
related mortality. Colorectal cancers develop slowly 
over many years, initially as a polyp in the inner lining 
of the colon or rectum, which may progress into 
cancerous lesions called adenocarcinomas. More than 
95 percent of colorectal cancers are adenocarcinomas. 
Removing the polyp early may prevent progession to  
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cancer. Other less common types of colorectal cancers 
include carcinoid tumors, gastrointestinal stromal 
tumors and lymphomas. 
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